Novavax, Inc. (VIE:NVAX)

Austria · Delayed Price · Currency is EUR

8.37

-0.19 (-2.23%)

At close: Mar 6, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development of Recombinant Vaccines	1.12B	682.16M	983.71M	1.98B	1.15B
Development of Recombinant Vaccines Growth	64.69%	-30.65%	-50.36%	72.89%	141.02%
Total	1.12B	682.16M	983.71M	1.98B	1.15B
Total Growth	64.69%	-30.65%	-50.36%	72.89%	141.02%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	405.61M	522.54M	443.89M	-	-
United States Growth	-22.38%	17.72%	-	-	-
Rest of North America	575.67M	4.46M	13.39M	-	-
Rest of North America Growth	12801.61%	-66.67%	-	-	-
Europe	15.74M	96.14M	271.96M	-	-
Europe Growth	-83.63%	-64.65%	-	-	-
Rest of The World	126.46M	59.02M	254.46M	-	-
Rest of The World Growth	114.26%	-76.80%	-	-	-
Total	1.12B	682.16M	983.71M	-	-
Total Growth	64.69%	-30.65%	-	-	-

Source: S&P Global Market Intelligence.